Advertisement
UK markets close in 1 hour 50 minutes

  • FTSE 100

    7,828.93
    -48.12 (-0.61%)
     

  • FTSE 250

    19,310.56
    -140.11 (-0.72%)
     

  • AIM

    743.07
    -2.22 (-0.30%)
     

  • GBP/EUR

    1.1675
    -0.0008 (-0.07%)
     

  • GBP/USD

    1.2463
    +0.0024 (+0.20%)
     

  • Bitcoin GBP

    51,866.32
    +2,005.34 (+4.02%)
     

  • CMC Crypto 200

    1,332.19
    +19.57 (+1.49%)
     

  • S&P 500

    5,006.77
    -4.35 (-0.09%)
     

  • DOW

    37,901.16
    +125.78 (+0.33%)
     

  • CRUDE OIL

    82.65
    -0.08 (-0.10%)
     

  • GOLD FUTURES

    2,395.60
    -2.40 (-0.10%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     

  • DAX

    17,710.99
    -126.41 (-0.71%)
     

  • CAC 40

    8,009.81
    -13.45 (-0.17%)
     
Property:

11 beautiful homes with glorious garden rooms

Investing in a home with a garden room will enable you to enjoy your outside space whatever the weather

AstraZeneca starts final-stage tests on severe asthma drug

Reuters - UK Focus

LONDON, Aug 14 (Reuters) - AstraZeneca (NYSE: AZN - news) said on Thursday it was starting final-stage Phase III clinical trials for its experimental drug tralokinumab as a treatment for severe asthma.

The drug, which showed promising results in mid-stage trials in May, was among those highlighted by AstraZeneca as part of its defence against an abortive $118 billion takeover bid by Pfizer (NYSE: PFE - news) .

Like many of AstraZeneca's biggest new drug hopes, the medicine was developed by MedImmune, the U.S.-based biotech company acquired by AstraZeneca in 2007.

Several firms are racing to develop injectable biotech asthma drugs for patients with severe disease who do not respond well to traditional inhalers, in pursuit of a new market worth a possible $7.5 billion a year. (Reporting by Ben Hirschler, Editing by Paul Sandle)